GlassScriptPhysician profile
Katherine Sandstrom
NPI 1982973095
$5,117.16
in general payments reported to CMS, 2019-2025
18 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.15 · 2022: $652 · 2023: $1,869 · 2024: $1,481 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,023 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,022.85 |
| Education | $353.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,895.68 | 2021-2025 | |
| Janssen Biotech, INC. | $785.53 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $550.19 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $529.59 | 2022-2024 | Sotyktu |
| Pfizer INC. | $436.80 | 2022-2025 | |
| Lilly USA, LLC | $404.85 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $113.35 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.13 | 2023-2025 | Dupixent |
| Amgen INC. | $65.13 | 2022-2025 | Otezla |
| Gt Medical Technologies, INC | $60.68 | 2023 | Gammatile |
| Incyte Corporation | $46.90 | 2022-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $35.11 | 2023-2025 | Ilumya |
| Leo Pharma INC. | $25.46 | 2025 | Anzupgo |
| Galderma Laboratories, L.P. | $24.70 | 2025 | Nemluvio |
| Ucb, INC. | $15.66 | 2025 | Bimzelx |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $14.99 | 2024 | Zoryve |
| Glaxosmithkline, LLC. | $13.24 | 2023 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Sandstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.